Belite Competitors
| BLTE Stock | USD 171.81 2.81 1.66% |
Belite Bio vs Crinetics Pharmaceuticals Correlation
Poor diversification
The correlation between Belite Bio ADR and CRNX is 0.77 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Belite Bio ADR and CRNX in the same portfolio, assuming nothing else is changed.
Moving together with Belite Stock
| 0.7 | ENTA | Enanta Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.66 | FHTX | Foghorn Therapeutics | PairCorr |
Moving against Belite Stock
| 0.79 | HUMA | Humacyte | PairCorr |
| 0.61 | EVAX | Evaxion Biotech AS | PairCorr |
| 0.58 | MYGN | Myriad Genetics | PairCorr |
| 0.42 | LTRN | Lantern Pharma | PairCorr |
| 0.41 | DNA | Ginkgo Bioworks Holdings | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Belite Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Belite Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Belite Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Belite and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Belite Bio ADR does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Belite Stock performing well and Belite Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Belite Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MIRM | 1.96 | 0.56 | 0.26 | 1.21 | 1.70 | 4.60 | 13.83 | |||
| LGND | 1.67 | 0.03 | 0.00 | 0.19 | 2.08 | 3.51 | 18.09 | |||
| ADMA | 2.22 | 0.13 | 0.06 | 0.12 | 2.62 | 5.01 | 13.78 | |||
| PRAX | 4.14 | 0.95 | 0.22 | 4.90 | 3.90 | 9.33 | 36.21 | |||
| ACAD | 1.61 | 0.11 | 0.07 | 0.14 | 1.51 | 3.31 | 9.79 | |||
| SLNO | 2.83 | (0.77) | 0.00 | (1.12) | 0.00 | 5.16 | 28.47 | |||
| DYN | 3.25 | (0.38) | 0.00 | (0.69) | 0.00 | 7.01 | 26.40 | |||
| ARQT | 2.66 | 0.45 | 0.18 | 0.95 | 2.09 | 6.75 | 32.59 | |||
| VKTX | 2.69 | (0.31) | 0.00 | (0.20) | 0.00 | 7.49 | 19.06 | |||
| CRNX | 2.18 | 0.20 | 0.07 | 0.52 | 2.45 | 3.94 | 19.30 |
Cross Equities Net Income Analysis
Compare Belite Bio ADR and related stocks such as Mirum Pharmaceuticals, Ligand Pharmaceuticals, and ADMA Biologics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (163.4 M) | (87.9 M) | (79.1 M) | (83.1 M) |
| LGND | (27.1 M) | 10.2 M | (527 K) | 11.4 M | 12 M | 257.3 M | (1.6 M) | 12.6 M | 143.3 M | 629.3 M | (3 M) | 57.1 M | (33.4 M) | 52.2 M | (4 M) | (4.6 M) | (4.4 M) |
| ADMA | (29.7 M) | (26.5 K) | (7.3 M) | (15.5 M) | (16.8 M) | (18 M) | (19.5 M) | (43.8 M) | (65.7 M) | (48.3 M) | (75.7 M) | (71.6 M) | (65.9 M) | (28.2 M) | 197.7 M | 227.3 M | 238.7 M |
| PRAX | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (35.5 M) | (61.8 M) | (166.9 M) | (213.1 M) | (123.3 M) | (182.8 M) | (164.5 M) | (172.8 M) |
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | 226.5 M | 203.8 M | 214 M |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
| ARQT | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (19.3 M) | (42 M) | (135.7 M) | (205.9 M) | (311.5 M) | (262.1 M) | (140 M) | (126 M) | (132.3 M) |
| VKTX | (444) | (444) | (444) | (146.2 K) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (85.9 M) | (110 M) | (99 M) | (94 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (268.6 M) | (255.1 M) |
Belite Bio ADR and related stocks such as Mirum Pharmaceuticals, Ligand Pharmaceuticals, and ADMA Biologics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Belite Bio ADR financial statement analysis. It represents the amount of money remaining after all of Belite Bio ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Belite Bio Competitive Analysis
The better you understand Belite Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Belite Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Belite Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Belite Bio Competition Performance Charts
Five steps to successful analysis of Belite Bio Competition
Belite Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Belite Bio ADR in relation to its competition. Belite Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Belite Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Belite Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Belite Bio ADR, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Belite Bio position
In addition to having Belite Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Belite Bio Correlation with its peers. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Biotechnology sector continue expanding? Could Belite diversify its offerings? Factors like these will boost the valuation of Belite Bio. Projected growth potential of Belite fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Belite Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Belite Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Belite Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Belite Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.